Bonus Biogroup Liabilities 2024

Bonus Biogroup Aktienanalyse

What does Bonus Biogroup do?

The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients. Bonus Biogroup ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Bonus Biogroup's Liabilities

Bonus Biogroup's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Bonus Biogroup's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Bonus Biogroup's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Bonus Biogroup's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Bonus Biogroup’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Bonus Biogroup stock

What is the level of liabilities of Bonus Biogroup this year?

Bonus Biogroup has a debt balance of 18.22 M ILS this year.

What were the liabilities of Bonus Biogroup compared to the previous year?

The liabilities of Bonus Biogroup have increased by -8.4% dropped compared to the previous year.

What are the consequences of high debt for investors of Bonus Biogroup?

High liabilities can pose a risk for investors of Bonus Biogroup, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Bonus Biogroup?

Low liabilities mean that Bonus Biogroup has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Bonus Biogroup affect the company?

An increase in liabilities of Bonus Biogroup can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Bonus Biogroup affect the company?

A decrease in the liabilities of Bonus Biogroup can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Bonus Biogroup?

Some factors that can influence the liabilities of Bonus Biogroup include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Bonus Biogroup so important for investors?

The liabilities of Bonus Biogroup are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Bonus Biogroup take to modify the liabilities?

To change its liabilities, Bonus Biogroup can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Bonus Biogroup pay?

Over the past 12 months, Bonus Biogroup paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bonus Biogroup is expected to pay a dividend of 0 ILS.

What is the dividend yield of Bonus Biogroup?

The current dividend yield of Bonus Biogroup is .

When does Bonus Biogroup pay dividends?

Bonus Biogroup pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bonus Biogroup?

Bonus Biogroup paid dividends every year for the past 0 years.

What is the dividend of Bonus Biogroup?

For the upcoming 12 months, dividends amounting to 0 ILS are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bonus Biogroup located?

Bonus Biogroup is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bonus Biogroup kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bonus Biogroup from 8/18/2024 amounting to 0 ILS, you needed to have the stock in your portfolio before the ex-date on 8/18/2024.

When did Bonus Biogroup pay the last dividend?

The last dividend was paid out on 8/18/2024.

What was the dividend of Bonus Biogroup in the year 2023?

In the year 2023, Bonus Biogroup distributed 0 ILS as dividends.

In which currency does Bonus Biogroup pay out the dividend?

The dividends of Bonus Biogroup are distributed in ILS.